- Home
- VTVT vs GANX Comparison
VTVT vs GANX Comparison
Compare VTVT & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- GANX
- Stock Information
- Founded
- VTVT 2015
- GANX 2017
- Country
- VTVT United States
- GANX United States
- Employees
- VTVT N/A
- GANX N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- GANX Health Care
- Exchange
- VTVT Nasdaq
- GANX Nasdaq
- Market Cap
- VTVT 56.7M
- GANX 57.9M
- IPO Year
- VTVT 2015
- GANX 2021
- Fundamental
- Price
- VTVT $16.67
- GANX $1.89
- Analyst Decision
- VTVT Strong Buy
- GANX Strong Buy
- Analyst Count
- VTVT 2
- GANX 5
- Target Price
- VTVT $35.50
- GANX $8.20
- AVG Volume (30 Days)
- VTVT 5.3K
- GANX 215.0K
- Earning Date
- VTVT 05-15-2025
- GANX 05-14-2025
- Dividend Yield
- VTVT N/A
- GANX N/A
- EPS Growth
- VTVT N/A
- GANX N/A
- EPS
- VTVT N/A
- GANX N/A
- Revenue
- VTVT $17,000.00
- GANX N/A
- Revenue This Year
- VTVT N/A
- GANX N/A
- Revenue Next Year
- VTVT N/A
- GANX N/A
- P/E Ratio
- VTVT N/A
- GANX N/A
- Revenue Growth
- VTVT N/A
- GANX N/A
- 52 Week Low
- VTVT $12.12
- GANX $0.89
- 52 Week High
- VTVT $26.99
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- VTVT 40.48
- GANX 49.54
- Support Level
- VTVT $15.92
- GANX $1.76
- Resistance Level
- VTVT $16.70
- GANX $2.08
- Average True Range (ATR)
- VTVT 0.98
- GANX 0.14
- MACD
- VTVT -0.37
- GANX 0.01
- Stochastic Oscillator
- VTVT 16.47
- GANX 42.65
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.